In-Vitro Diagnostics Comprehensive Study by Type (Reagents & Kits, Instruments (Fully Automated Instruments, Semi-Automated Instruments, and Other Instruments), Data Management Software and Services), Application (Diabetes, Infectious Diseases, Oncology, Cardiology, Autoimmune Diseases, Nephrology, Drug Testing/Pharmacogenomics, HIV/Aids, Other Applications), Technology (Immunoassay/Immunochemistry (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Rapid Test, and Western Blotting, Enzyme-Linked Immunospot Assays), Clinical Chemistry (Basic Metabolic Panel, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Panel, and Specialty Chemical Tests), Molecular Diagnostics (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Microarray, Hybridization, DNA Sequencing & Next-Generation Sequencing, and Other Molecular Diagnostics Technologies), Coagulation and Hemostasis, Microbiology, Hematology, Urinalysis, Other IVD Technologies), End User (Diagnostics Laboratories, Hospitals, Point-Of-Care Testing, Patient Self-Testing, Academic Institutes, Other End Users) Players and Region - Global Market Outlook to 2030

In-Vitro Diagnostics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
In-Vitro Diagnostics (IVD) is useful for the detection of any kind of infection & diseases by taking the sample from the human body to treat diseases or its sequelae. In-vitro diagnostics products include instruments, reagents, as well as any system used for the diagnosis of diseases. The growing incidence of chronic as well as infectious diseases coupled with increasing geriatric population around the globe are the factors that drive global IVD market growth. Moreover, a growing number of public as well as private diagnostic centers & point of care testing centers are likely to impel the in-vitro diagnostics market growth over the coming years.

Highlights from In-Vitro Diagnostics Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia-Pacific
Largest MarketNorth America
Forecast Value (2030)USD 89.74 Billion
UnitValue (USD Billion)
CAGR20.3%


The key Players profiled in the report are Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (United States), Abbott Laboratories (United States), Thermo Fisher Scientific (United States), Johnson & Johnson (United States), Becton, Dickinson and Company (United States), Bio-Rad Laboratories (United States), Sysmex Corporation (Japan), bioMérieux (France) and DiaSorin (Italy). Additionally, other players that are part of this comprehensive study are Ortho Clinical Diagnostics (United States), Agilent Technologies (United States) and QIAGEN (Germany).

Geographic Breakdown and Segment Analysis
The Global In-Vitro Diagnostics market presents a comprehensive analysis of the In-Vitro Diagnostics market by product type (Reagents & Kits, Instruments (Fully Automated Instruments, Semi-Automated Instruments, and Other Instruments) and Data Management Software and Services), by end-user/application (Diabetes, Infectious Diseases, Oncology, Cardiology, Autoimmune Diseases, Nephrology, Drug Testing/Pharmacogenomics, HIV/Aids and Other Applications), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global In-Vitro Diagnostics industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the North America holds majority of market share of the In-Vitro Diagnostics market

Analyst at AMA have segmented the market study of Global In-Vitro Diagnostics market by Type, Application and Region.

Influencing Trend:
Increasing Awareness on Personalized Medicine

Market Growth Drivers:
Rising Aged Population & Growing Occurrence of Chronic and Infectious Diseases, Mounting Acceptance of Automation in Laboratories & Fully Automated Instruments and Growing Acceptance of Point-Of-Care Testing

Challenges:
Constantly Changing Regulatory Landscape

Restraints:
Hostile Reimbursement Scenario

Opportunities:
Advancement of Condition-Specific Markers & Tests and Growth Opportunities in Emerging Nations

Market Developments Activities:
In may 2022 bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures
In November 2023, Roche Roche announced the launch of the LightCycler® PRO System based on the proven gold standard technology of the LightCycler® Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in-vitro diagnostics

Regulatory Insights:
As per, United States Food and Drug Administration (FDA), IVDs are medical devices as defined in section 210(h) of the Federal Food, Drug, and Cosmetic Act, and may also be biological products subject to section 351 of the Public Health Service Act. Like other medical devices, IVDs are subject to premarket & postmarket controls. IVDs are also subject to the Clinical Laboratory Improvement Amendments (CLIA '88) of 1988.



Key Target Audience
In-Vitro Diagnostics Product Manufacturers, OEM Manufacturers, Pathologists and Pathology Laboratories, Group Purchase Organizations (GPOs), Distributors of IVD Products, Hospitals and Clinics and Healthcare Institutions, and Research Institutes

Report Objectives / Segmentation Covered

By Type
  • Reagents & Kits
  • Instruments (Fully Automated Instruments, Semi-Automated Instruments, and Other Instruments)
  • Data Management Software and Services
By Application
  • Diabetes
  • Infectious Diseases
  • Oncology
  • Cardiology
  • Autoimmune Diseases
  • Nephrology
  • Drug Testing/Pharmacogenomics
  • HIV/Aids
  • Other Applications
By Technology
  • Immunoassay/Immunochemistry (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Rapid Test, and Western Blotting, Enzyme-Linked Immunospot Assays)
  • Clinical Chemistry (Basic Metabolic Panel, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Panel, and Specialty Chemical Tests)
  • Molecular Diagnostics (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Microarray, Hybridization, DNA Sequencing & Next-Generation Sequencing, and Other Molecular Diagnostics Technologies)
  • Coagulation and Hemostasis
  • Microbiology
  • Hematology
  • Urinalysis
  • Other IVD Technologies

By End User
  • Diagnostics Laboratories
  • Hospitals
  • Point-Of-Care Testing
  • Patient Self-Testing
  • Academic Institutes
  • Other End Users

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Aged Population & Growing Occurrence of Chronic and Infectious Diseases
      • 3.2.2. Mounting Acceptance of Automation in Laboratories & Fully Automated Instruments
      • 3.2.3. Growing Acceptance of Point-Of-Care Testing
    • 3.3. Market Challenges
      • 3.3.1. Constantly Changing Regulatory Landscape
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness on Personalized Medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global In-Vitro Diagnostics, by Type, Application, Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
  • 6. In-Vitro Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Diagnostics (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Siemens Healthineers (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio-Rad Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sysmex Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioMérieux (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. DiaSorin (Italy)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global In-Vitro Diagnostics Sale, by Type, Application, Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Company Basic Information, Sales Area and Its Competitors
  • Table 12. Research Programs/Design for This Report
  • Table 13. Key Data Information from Secondary Sources
  • Table 14. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global In-Vitro Diagnostics share by Players 2023 (%)
  • Figure 5. Global In-Vitro Diagnostics share by Players (Top 3) 2023(%)
  • Figure 6. Global In-Vitro Diagnostics share by Players (Top 5) 2023(%)
  • Figure 7. BCG Matrix for key Companies
  • Figure 8. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 9. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 10. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 11. Siemens Healthineers (Germany) Revenue: by Geography 2023
  • Figure 12. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 13. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 14. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 15. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 20. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 22. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 24. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Sysmex Corporation (Japan) Revenue: by Geography 2023
  • Figure 26. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 27. BioMérieux (France) Revenue: by Geography 2023
  • Figure 28. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 29. DiaSorin (Italy) Revenue: by Geography 2023
List of companies from research coverage that are profiled in the study
  • Roche Diagnostics (Switzerland)
  • Siemens Healthineers (Germany)
  • Danaher Corporation (United States)
  • Abbott Laboratories (United States)
  • Thermo Fisher Scientific (United States)
  • Johnson & Johnson (United States)
  • Becton, Dickinson and Company (United States)
  • Bio-Rad Laboratories (United States)
  • Sysmex Corporation (Japan)
  • bioMérieux (France)
  • DiaSorin (Italy)
Additional players considered in the study are as follows:
Ortho Clinical Diagnostics (United States) , Agilent Technologies (United States) , QIAGEN (Germany)
Select User Access Type

Key Highlights of Report


Mar 2024 214 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.

Know More About Global In-Vitro Diagnostics Market research Report?